{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:49:43Z","timestamp":1787014183230,"version":"build-2736575974"},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The management of antiseizure treatment in patients with epilepsy relies on the benefit\u2013risk ratio. Data on antiseizure medication (ASM) use in children are limited. We described antiseizure medication use in children with epilepsy (CwE) in France, with a focus on the chronic use of benzodiazepines and related implications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a 5\u2010year cohort study from January 2012, using data from the French national health care data system (Syst\u00e8me National des Donn\u00e9es de Sant\u00e9). We included CwE identified through International Classification of Diseases, 10th Revision codes and medications from January 2012 to December 2015 and followed them until December 2016. We described ASMs and assessed whether the risk of initiating a polytherapy after a bitherapy depends on whether benzodiazepine was included in the bitherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified 62\u2009885 CwE. Valproate was the most reimbursed ASM (40%), followed by lamotrigine (17.6%), levetiracetam (9.3%), clobazam (6.1%), and carbamazepine (5.8%). Prescriptions were initiated at the hospital in 74.5% of CwE. We observed a decrease in the number of CwE with at least one benzodiazepine reimbursement from 15.3% in 2013 to 10.1% in 2016 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.0001). The prevalence of CwE with levetiracetam reimbursements increased, whereas that of CwE with valproate decreased. A switch from a bitherapy to a polytherapy was more likely when the bitherapy included a benzodiazepine (subdistribution hazard ratio [sHR]\u2009=\u20091.20 [1.03\u20131.39]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance<\/jats:title>\n                    <jats:p>The prevalence of CwE with at least one benzodiazepine reimbursement decreased during the study period. Benzodiazepines were associated with an increased use of subsequent ASM polytherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/epi.17906","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T07:43:29Z","timestamp":1707896609000},"page":"900-908","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Benzodiazepines for pediatric epilepsies and their risks in a cohort within the French health care data"],"prefix":"10.1111","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3874-9749","authenticated-orcid":false,"given":"St\u00e9phane","family":"Auvin","sequence":"first","affiliation":[{"name":"INSERM NeuroDiderot Universit\u00e9 Paris Cit\u00e9  Paris France"},{"name":"Pediatric Neurology Department, CRMR Epilepsies Rares, EpiCARE member AP\u2010HP, Robert Debr\u00e9 University Hospital  Paris France"},{"name":"Institut Universitaire de France  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Guillo","sequence":"additional","affiliation":[{"name":"INSERM, Institut Pierre Louis d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique Sorbonne Universit\u00e9  Paris France"},{"name":"Centre de Pharmaco\u00e9pid\u00e9miologie (Cephepi), CIC\u20101901 AP\u2010HP, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"de Rycke","sequence":"additional","affiliation":[{"name":"INSERM, Institut Pierre Louis d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique Sorbonne Universit\u00e9  Paris France"},{"name":"Centre de Pharmaco\u00e9pid\u00e9miologie (Cephepi), CIC\u20101901 AP\u2010HP, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re  Paris France"},{"name":"D\u00e9partement de Sant\u00e9 Publique AP\u2010HP, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diep","family":"Tran","sequence":"additional","affiliation":[{"name":"Centre de Pharmaco\u00e9pid\u00e9miologie (Cephepi), CIC\u20101901 AP\u2010HP, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3590-4638","authenticated-orcid":false,"given":"Florence","family":"Tubach","sequence":"additional","affiliation":[{"name":"INSERM, Institut Pierre Louis d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique Sorbonne Universit\u00e9  Paris France"},{"name":"Centre de Pharmaco\u00e9pid\u00e9miologie (Cephepi), CIC\u20101901 AP\u2010HP, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re  Paris France"},{"name":"D\u00e9partement de Sant\u00e9 Publique AP\u2010HP, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528\u20101167.2009.02397.x"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14596"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2016.1195809"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.15337"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2011.01.004"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24427"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e6231"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.10.006"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u20100404.2008.01004.x"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.respe.2017.05.004"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4233"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2014.07.013"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3532"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12666"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431\u2010019\u201003556\u20109"},{"key":"e_1_2_12_17_1","first-page":"162","article-title":"Changes in the use of antiseizure medications with focus on children and adolescents in Norway 2009\u20132018","volume":"62","author":"Heger K","year":"2021","journal-title":"Epilepsia"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17181"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab162"},{"key":"e_1_2_12_20_1","unstructured":"Available from:http:\/\/dev4\u2010afssaps\u2010marche2017.integra.fr\/S\u2010informer\/Informations\u2010de\u2010securite\u2010Lettres\u2010aux\u2010professionnels\u2010de\u2010sante\/Rivotril\u2010clonazepam\u2010Modification\u2010des\u2010conditions\u2010de\u2010prescription\u2010et\u2010de\u2010delivrance\u2010Lettre\u2010aux\u2010professionnels\u2010de\u2010sante\u2010Actualise\u2010le\u201004\u201001\u20102012"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102015\u2010008298"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.17906","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T05:54:07Z","timestamp":1732859647000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.17906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1111\/epi.17906"],"URL":"https:\/\/doi.org\/10.1111\/epi.17906","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,14]]},"assertion":[{"value":"2023-09-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}